Grufity logoGrufity logo

Inspire Medical Systems Inc Stock Research

INSP

253.71USD+11.65(+4.81%)Market Closed

Market Summary

USD253.71+11.65
Market Closed
4.81%

INSP Alerts

INSP Stock Price

INSP RSI Chart

INSP Valuation

Market Cap

7.4B

Price/Earnings (Trailing)

-163.98

Price/Sales (Trailing)

18.04

EV/EBITDA

-169.84

Price/Free Cashflow

3.0K

INSP Price/Sales (Trailing)

INSP Profitability

EBT Margin

-10.85%

Return on Equity

-9.05%

Return on Assets

-7.95%

Free Cashflow Yield

0.03%

INSP Fundamentals

INSP Revenue

Revenue (TTM)

407.9M

Revenue Y/Y

75.9%

Revenue Q/Q

26.3%

INSP Earnings

Earnings (TTM)

-44.9M

Earnings Y/Y

231.74%

Earnings Q/Q

118.7%

Price Action

52 Week Range

142.74282.31
(Low)(High)

Last 7 days

-4.5%

Last 30 days

-10.7%

Last 90 days

-5.3%

Trailing 12 Months

16.7%

INSP Financial Health

Current Ratio

8.66

INSP Investor Care

Shares Dilution (1Y)

5.81%

Diluted EPS (TTM)

-1.6

Peers (Alternatives to Inspire Medical Systems)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
104.1B
18.4B
2.26% 8.00%
44.16
5.64
7.84% 18.25%
84.2B
6.2B
-4.47% -13.27%
63.66
13.53
8.97% -22.43%
69.1B
12.7B
0.59% 12.45%
99.06
5.45
6.68% -32.95%
67.4B
19.0B
-5.16% -6.78%
41.86
3.55
-0.43% -8.78%
49.8B
5.4B
2.41% -25.12%
32.74
9.26
2.86% 1.25%
MID-CAP
10.2B
847.1M
-3.64% 34.52%
-5.1K
12.05
13.32% -137.89%
7.4B
407.9M
-10.70% 16.71%
-163.98
18.04
74.75% -6.75%
5.2B
1.0B
-11.64% -20.31%
30.19
5.09
6.76% 24.45%
3.5B
410.9M
4.51% -3.13%
-29.82
8.43
27.29% -14.60%
2.5B
1.3B
1.97% -58.05%
451.35
1.97
14.48% -92.74%
SMALL-CAP
1.7B
181.0M
12.30% -10.66%
-11.1
9.15
31.19% -48.60%
1.3B
820.0M
-8.35% -12.22%
25.89
1.59
10.13% 701.59%
33.3M
29.3M
-34.48% -66.75%
-2.27
1.14
-19.35% -69.01%
2.7M
6.8M
-26.89% 55.78%
-0.12
0.4
-21.00% -36.01%

Financials for Inspire Medical Systems

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue17.1%407,856,000348,354,000300,851,000262,424,000233,394,000
Gross Profit16.5%341,741,000293,235,000256,894,000225,122,000200,115,000
Operating Expenses13.7%389,333,000342,313,000298,574,000265,339,000239,965,000
  S&GA Expenses12.7%320,688,000284,622,000252,262,000224,273,000202,615,000
  R&D Expenses19.0%68,645,00057,691,00046,312,00041,066,00037,350,000
EBITDA11.6%-40,733,000-46,066,000-40,105,000-38,939,000-
EBITDA Margin24.5%-0.10-0.13-0.13-0.15-
Earnings Before Taxes11.3%-44,268,000-49,914,000-43,657,000-42,371,000-41,970,000
EBT Margin24.3%-0.11-0.14-0.15-0.16-
Interest Expenses-24.3%1,677,0002,215,0002,096,0002,132,0002,128,000
Net Income11.0%-44,881,000-50,422,000-43,922,000-42,520,000-42,042,000
Net Income Margin24.0%-0.11-0.14-0.15-0.16-
Free Cahsflow118.1%2,473,000-13,645,000-22,624,000-27,028,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets7.1%565528292290295
  Current Assets7.0%530496263262269
    Cash Equivalents5.7%442418187203214
  Inventory-21.5%12.0015.0022.0022.0017.00
  Net PPE22.0%17.0014.0011.009.008.00
Liabilities20.1%69.0057.0065.0065.0066.00
  Current Liabilities24.1%61.0049.0047.0043.0041.00
Shareholder's Equity5.5%496470227225229
  Retained Earnings1.0%-324-327-310-296-279
  Additional Paid-In Capital2.8%820798538521508
Shares Outstanding0.7%29.0029.0028.0028.0027.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations266.1%12.00-6.97-18.31-22.47-20.12
  Share Based Compensation18.1%52.0044.0036.0030.0026.00
Cashflow From Investing-14.1%-19.60-17.1817.0029.0029.00
Cashflow From Financing1.4%23523212.0014.0015.00

Risks for INSP

What is the probability of a big loss on INSP?

88.3%


Probability that Inspire Medical Systems stock will be more than 20% underwater in next one year

70.8%


Probability that Inspire Medical Systems stock will be more than 30% underwater in next one year.

29.6%


Probability that Inspire Medical Systems stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does INSP drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Inspire Medical Systems was unfortunately bought at previous high price.

Drawdowns

Returns for INSP

Cumulative Returns on INSP

54.8%


3-Year Cumulative Returns

Which funds bought or sold INSP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
reduced
-12.18
67,312
343,312
0.01%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-33.45
-2,771,990
47,631,000
0.05%
2023-03-10
BAILLIE GIFFORD & CO
unchanged
-
11,805
40,805
-%
2023-03-06
Rockefeller Capital Management L.P.
added
18.52
91,000
225,000
-%
2023-02-28
Voya Investment Management LLC
added
413
21,095,500
24,450,500
0.04%
2023-02-24
NATIXIS
added
54.00
2,196,350
4,166,350
0.02%
2023-02-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
new
-
602,000
602,000
0.01%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
added
375
12,358
14,358
-%
2023-02-21
MACQUARIE GROUP LTD
reduced
-24.66
17,372,000
267,162,000
0.32%
2023-02-17
TRUIST FINANCIAL CORP
reduced
-20.29
301,312
2,587,310
-%

1–10 of 48

Latest Funds Activity

Are funds buying INSP calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own INSP
No. of Funds

Inspire Medical Systems News

Yahoo Finance

Inspire Medical Systems (INSP) Outperformed on 2023 Revenue Guidance.

Yahoo Finance,
4 days ago

Investor's Business Daily

Investor's Business Daily

Investor's Business Daily

Investor's Business Daily

Zacks Investment Research

Best Momentum Stocks to Buy for February 21st.

Zacks Investment Research,
27 days ago

Zacks Investment Research

Best Momentum Stocks to Buy for February 17th.

Zacks Investment Research,
31 days ago

Schedule 13G FIlings of Inspire Medical Systems

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
10.31%
2,978,391
SC 13G/A
Jan 31, 2023
blackrock inc.
7.4%
2,135,708
SC 13G/A
Nov 10, 2022
vanguard group inc
10.04%
2,899,902
SC 13G/A
Feb 03, 2022
blackrock inc.
6.7%
1,846,227
SC 13G/A
Jan 10, 2022
fmr llc
-
0
SC 13G/A
Feb 12, 2021
orbimed advisors llc
0.00%
0
SC 13G/A
Feb 10, 2021
vanguard group inc
8.92%
2,401,971
SC 13G
Feb 08, 2021
fmr llc
-
0
SC 13G/A
Feb 02, 2021
blackrock inc.
7.4%
1,993,714
SC 13G

INSP Fair Value

Inspire Medical Systems fair value in different scenarios

The table shows the Fair Value estimates for Inspire Medical Systems for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

8.17

-96.78%

12.73

-94.98%

30.42

-88.01%

60.76

-76.05%

121.35

-52.17%
Current Inflation

7.83

-96.91%

11.86

-95.33%

27.20

-89.28%

53.06

-79.09%

104.43

-58.84%
Very High Inflation

7.40

-97.08%

10.81

-95.74%

23.40

-90.78%

44.12

-82.61%

85.00

-66.50%

Historical Inspire Medical Systems Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Inspire Medical Systems

View All Filings
Date Filed Form Type Document
Mar 13, 2023
4
Insider Trading
Mar 13, 2023
4/A
Insider Trading
Mar 13, 2023
4/A
Insider Trading
Mar 10, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Feb 28, 2023
4
Insider Trading
Feb 21, 2023
4
Insider Trading
Feb 14, 2023
4
Insider Trading
Feb 14, 2023
4
Insider Trading
Feb 14, 2023
4
Insider Trading

Latest Insider Trading transactions for INSP

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-08
Rondoni John
acquired
9,081
2.07
4,387
chief technology officer
2023-03-01
Ban Randy
sold
-83,531,100
8,353
-10,000
chief commercial officer
2023-03-01
Ban Randy
acquired
9,400
0.94
10,000
chief commercial officer
2023-02-27
Jandrich Steven
gifted
-
-
128
vp, human resources
2023-02-27
Jandrich Steven
gifted
-
-
-128
vp, human resources
2023-02-24
Jandrich Steven
gifted
-
-
-256
vp, human resources
2023-02-24
Jandrich Steven
gifted
-
-
128
vp, human resources
2023-02-16
Ebeling Philip
sold
-1,925,000
275
-7,000
chief operating officer
2023-02-16
Ebeling Philip
acquired
1,363,740
194
7,000
chief operating officer
2023-02-15
Herbert Timothy P.
sold
-3,223,620
275
-11,715
ceo and president

1–10 of 50

Timothy P. Herbert
480
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

INSP Income Statement

2022-09-30
Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Revenue$ 109,188$ 61,685$ 269,956$ 154,996
Cost of goods sold19,7868,62443,96322,123
Gross profit89,40253,061225,993132,873
Operating expenses:    
Research and development20,9939,61447,39727,056
Selling, general and administrative85,60353,243225,853143,846
Total operating expenses106,59662,857273,250170,902
Operating loss(17,194)(9,796)(47,257)(38,029)
Other expense (income):    
Interest and dividend income(1,350)(22)(1,681)(110)
Interest expense6565371,6771,590
Other expense, net1013329090
Total other (income) expense(593)5482861,570
Loss before income taxes(16,601)(10,344)(47,543)(39,599)
Income taxes246348852
Net loss(16,847)(10,347)(48,031)(39,651)
Other comprehensive loss:    
Foreign currency translation loss(148)0(106)0
Unrealized (loss) gain on investments(14)3(202)(38)
Total comprehensive loss$ (17,009)$ (10,344)$ (48,339)$ (39,689)
Net loss per share, basic (in dollars per share)$ (0.60)$ (0.38)$ (1.73)$ (1.46)
Net loss per share, diluted (in dollars per share)$ (0.60)$ (0.38)$ (1.73)$ (1.46)
Weighted average common shares used to compute net loss per share, basic (in shares)28,226,34527,300,37727,782,09327,225,499
Weighted average common shares used to compute net loss per share, diluted (in shares)28,226,34527,300,37727,782,09327,225,499

INSP Balance Sheet

2022-09-30
Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 417,808$ 214,467
Investments, short-term9,7410
Accounts receivable, net of allowance for credit losses of $34 and $99, respectively48,49834,179
Inventories15,14617,231
Prepaid expenses and other current assets4,3512,660
Total current assets495,544268,537
Investments, long-term09,938
Property and equipment, net14,1348,486
Operating lease right-of-use assets7,1417,919
Other non-current assets10,704204
Total assets527,523295,084
Current liabilities:  
Accounts payable20,30511,665
Accrued expenses28,98620,454
Notes payable, current portion09,188
Total current liabilities49,29141,307
Notes payable, non-current portion015,799
Operating lease liabilities, non-current portion7,8828,796
Other non-current liabilities146134
Total liabilities57,31966,036
Stockholders' equity:  
Preferred Stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding00
Common Stock, $0.001 par value per share; 200,000,000 shares authorized; 28,820,680 and 27,416,106 issued and outstanding at September 30, 2022 and December 31, 2021, respectively2927
Additional paid-in capital797,958508,465
Accumulated other comprehensive loss(363)(55)
Accumulated deficit(327,420)(279,389)
Total stockholders' equity470,204229,048
Total liabilities and stockholders' equity$ 527,523$ 295,084